Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Uncomplicated Plasmodium Falciparum Malaria
Interventions
DRUG

Artemether-lumefantrine and Amodiaquine Drug Combination

AL and AQ will be given together for three days then followed by placebo for three days

DRUG

Artemether-lumefantrine then Artesunate amodiaquine

AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days

DRUG

Artemether-lumefantrine

This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days

Trial Locations (2)

255

RECRUITING

Kibindu, Bagamoyo

+255

SUSPENDED

Yombo Dispensary, Bagamoyo

All Listed Sponsors
collaborator

The Swedish Research Council

OTHER_GOV

collaborator

Uppsala University

OTHER

lead

Muhimbili University of Health and Allied Sciences

OTHER